On Air Now

Tune in to Listen

93.9 FM Hibbing, MN

Weather

Current Conditions(Hibbing,MN 55746)

More Weather »
56° Feels Like: 56°
Wind: NW 0 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Clear 51°

Tomorrow

Mostly Sunny 78°

Thurs Night

Mostly Clear 51°

Alerts

  • 0 Severe Weather Alerts
  • 0 Cancellations

GlaxoSmithKline files for European approval of diabetes drug albiglutide

Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. REUTERS/Toby Melville
Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. REUTERS/Toby Melville

LONDON (Reuters) - Britain's biggest drugmaker GlaxoSmithKline said on Thursday it had filed for European approval of its new once-weekly diabetes drug albiglutide, as tries to gain a foothold in a crowded market.

Albiglutide, used to treat type 2 diabetes, belongs to the same class of injectable GLP-1 medicines as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca's Amylin unit.

The drug has not yet been approved anywhere in the world, GSK said.

As a latecomer to the GLP-1 market, however, analysts believe albiglutide may struggle to generate major sales.

GSK made a similar submission in the United States in January for albiglutide, one of a number of new drugs the company hopes will revive its product portfolio.

(Reporting by Alice Baghdjian; Editing by Paul Sandle)

Comments